Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family
2012-11-30 12:13:33 -
ORION CORPORATION STOCK EXCHANGE RELEASE 30 NOVEMBER 2012 at 1:10 PM EET
Orion Corporation is developing a budesonide-formoterol formulation combining
budesonide as an anti-inflammatory agent and formoterol as a long-acting
bronchodilator to expand the range of the inhalable Easyhaler(®) drug product
family for treatment of asthma and COPD.
Based on the favorable pharmacokinetic study results of this Easyhaler-
development programme Orion is planning to apply for a marketing authorisation
for the combined budesonide-formoterol formulation. Orion currently estimates
that the marketing authorisation application would be submitted in Europe during
the first half of 2013.
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Reijo Salonen, Senior Vice President, Research and Development (as of Monday
tel. +358 50 966 3647
Jari Karlson, CFO
tel. +358 50 966 2883
Orionintie 1A, FI-02200 Espoo
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE